Clinical Trials
80
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (60 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
- Conditions
- Type II Hyperlipidaemia
- Interventions
- Drug: PlaceboDrug: JTT-705 300mgDrug: JTT-705 600mgDrug: JTT-705 900mg
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2008-05-29
- Lead Sponsor
- Japan Tobacco Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT00686010
- Locations
- 🇳🇱
Amsterdam, Utrecht, Rotterdam, Nijmegen, Arnhem, Groningen, Dordrecht, Hoorn, Groningen, Amsterdam, Netherlands
News
LEO Pharma Launches Phase 2a Trial of Delgocitinib Cream for Rare Skin Disease Palmoplantar Pustulosis
LEO Pharma has initiated the DELTA NEXT phase 2a trial to evaluate delgocitinib cream versus placebo in adults with mild to severe palmoplantar pustulosis, a rare inflammatory skin condition.
Shionogi to Acquire Japan Tobacco's Pharmaceutical Subsidiaries for $1.1 Billion
Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities.
Shionogi Receives Regulatory Clearance for Torii Pharmaceutical Acquisition, Tender Offer Proceeds
Shionogi received a "Notice of Non-issuance of Cease and Desist Order" from Japan's Fair Trade Commission on May 28, 2025, clearing regulatory hurdles for its tender offer to acquire Torii Pharmaceutical.
LEO Pharma's Delgocitinib Cream Outperforms Alitretinoin in Landmark DELTA FORCE Trial for Chronic Hand Eczema
The phase 3 DELTA FORCE trial demonstrated superior efficacy of topical delgocitinib cream over oral alitretinoin capsules for severe chronic hand eczema, with results published in The Lancet.
D-Wave and Japan Tobacco Pioneer Quantum-Enhanced AI for Drug Discovery
D-Wave Quantum Inc. and Japan Tobacco have successfully completed a proof-of-concept project that combines quantum computing with AI to accelerate drug discovery, outperforming classical computing methods.
EMA Recommends Approval of Averoa's XOANACYL for Chronic Kidney Disease Treatment
The European Medicines Agency's CHMP has issued a positive opinion for XOANACYL, an oral therapy for chronic kidney disease, with final European Commission approval expected by June 2025.